News Heart drug biotech Kardigan raises $400m in upscaled IPO Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.
News Heart drug developer Kardigan files IPO The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
News Lila Sciences' swollen first round, and other biofinancings AI-powered autonomous lab firm Lila Sciences upsizes its Series A to $350m, heading a bumper week for new biotech financings.
News Kardigan raises $300m for cardio work, and other financings Kardigan makes its debut with a teal of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
